Traditionally, the appearance of microalbuminuria has been used to detect the onset of diabetic nephropathy (DN), and its appearance prompts aggressive treatment. A new marker has now been found that can indicate nephropathy before microalbuminuria is present….

As widely expected, the US Institute of Medicine (IOM) is advising the FDA that it should set stricter federal standards for the amount of salt that food manufacturers, restaurants, and food-service companies can add to their products….

The effect of a balanced, carbohydrate-counting diet on glycemic control in Type 1 diabetic subjects is unclear. The aim of the study was to determine its effect in a pilot trial….

Patients with diabetic nephropathy (kidney disease caused by diabetes) who received high dose B-vitamin therapy experienced a more rapid decline in kidney function and had a higher rate of heart attack and stroke than patients who received placebo, according to a study….

Four unhealthy behaviors — smoking, lack of physical activity, poor diet and alcohol consumption — appear to be associated with a substantially increased risk of death when combined, according to a report in JAMA….

Glucose levels tend to rise, study finds, as youths control their own care….

The results suggest that very early identification of dysglycemia may provide at-risk individuals with ample time to make long-lasting lifestyle changes that could prevent future diabetes….

Without a doubt, growth in the use of safety technologies will have a major impact on decreasing medical errors. For example, safety will improve with….  

Dear Clinician: If you could make sure all of your patients received diabetes education and extended diabetes management from the first day of diagnosis, would you be interested? If this could be done either in your office or close by, would you be interested? If this could be done with …

CeQur Insulin Pump Patch for Type 2’s   The CeQur insulin pump patch is a small, discreet and wearable insulin patch infuser for the continuous subcutaneous delivery of rapid acting insulin. The CeQur Device, which is not yet approved, features up to three days of consistent basal infusion (on-demand bolus …